PFSAHealthcare · Medical Devices

PFSA Stock Forecast: Profusa, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$5.46

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 13 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap

$1.4M

Ticker Nerd rank

13 / 100

Median analyst target

—

Analysts covering

—

Ticker Nerd rank

PFSA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Profusa, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

13 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Growth

Momentum

Revisions

Volatility

Issuance

Quality

Value

Size (98): Smaller than most of the companies we track.

Value (0): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PFSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PFSA, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PFSA appears on the weeks it earns a place.

Estimates

PFSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Profusa, Inc. (PFSA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.0×
Price / sales: —
Price / book: −0.0×
EV / EBITDA: −0.5×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: 134.4%
Return on assets: −725.3%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PFSA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
PFSAProfusa, Inc.	$1.4M	13
VTAKCatheter Precision, Inc.	$3.0M	27
GCTKGlucoTrack, Inc.	$3.7M	10
BJDXBluejay Diagnostics, Inc.	$4.1M	20
IVFINVO Fertility, Inc.	$2.7M	31
NUWENuwellis, Inc.	$4.2M	17
FEEDENvue Medical, Inc.	$4.3M	23

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Profusa, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PFSA news & analysis

Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company

GlobeNewsWire · 20 Aug 2026neutral

Profusa announced its Q2 2026 financial results and progress on the option agreement conditions to close with G3 Vision Labs, a commercial-stage diagnostics company. Debt and liability holders have executed $10.7 million of Series A Convertible Exchange Agreements, of which $4.57 million was converted into Series A Convertible Preferred Stock.

Why it matters — A PFSA watcher would care because the Series A conversion activity and progress toward closing with G3 Vision Labs signal advancement of the company's financing and strategic transaction.

Profusa Announces 1-for-4 Reverse Stock Split

GlobeNewsWire · 13 Aug 2026neutral

Profusa, Inc. announced it filed an amendment to effect a one-for-four reverse stock split of its common stock, effective at 12:01 am Eastern Time on August 17, 2026. The company's stock will begin trading on a post-split basis on The Nasdaq Capital Market on that date under its existing ticker symbol PFSA with a new CUSIP number.

Why it matters — PFSA watchers would care because the reverse stock split will reduce the number of outstanding shares and change the trading structure of the company's stock, potentially affecting its share price and per-share metrics.

Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs

GlobeNewsWire · 31 July 2026positive

Profusa announced it has signed an Option Agreement granting the right, but not the obligation, to acquire G3 Vision Labs, a commercial stage diagnostics company with estimated 2025 net revenues of approximately $111 million.

Why it matters — The agreement gives Profusa a potential pathway to acquire a revenue-generating diagnostics business, which could expand its commercial footprint beyond biosensing technologies.

Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company

GlobeNewsWire · 27 July 2026neutral

Profusa announced it has signed a non-binding term sheet to acquire a privately held, commercial-stage health diagnostics and toxicology testing company.

Why it matters — A PFSA watcher would care because this potential acquisition could mark a strategic shift for Profusa from a development-stage biosensing company toward a commercial-stage diagnostics business.

FAQ

Frequently asked questions about PFSA stock

How does Ticker Nerd's model rank PFSA?

As at 22 Aug 2026, Profusa, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the PFSA stock forecast for 2030?

No analyst covering Profusa, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PFSA are extrapolating price history, which says nothing about the business.

What does Profusa, Inc. do?

Profusa, Inc. is a digital health and medical technology company focused on bioengineered biosensors that continuously measure body chemistry for personal and clinical use.

What is the latest news on PFSA?

The most recent item we track (GlobeNewsWire, 20 Aug 2026): "Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company". Profusa announced its Q2 2026 financial results and progress on the option agreement conditions to close with G3 Vision Labs, a commercial-stage diagnostics company. Debt and liability holders have executed $10.7 million of Series A Convertible Exchange Agreements, of which $4.57 million was converted into Series A Convertible Preferred Stock.

Company

About Profusa, Inc.

Profusa, Inc. is a digital health and medical technology company focused on bioengineered biosensors that continuously measure body chemistry for personal and clinical use. The company’s current product portfolio centers on the Lumee platform, including Lumee Oxygen for tissue oxygen monitoring in vascular and wound-care settings and Lumee Glucose, which is being developed for continuous glucose monitoring. Profusa’s technology is designed to integrate with the body and generate medical-grade data that can support chronic disease management, perioperative care, and broader wellness applications. Based in Berkeley, California, Profusa operates at the intersection of biosensing, digital health, and medical diagnostics, serving healthcare providers and patients who need long-duration, real-time physiological monitoring.

CEO Mr. Jack E. Stover CPA · United States · https://profusa.com